Ze'ev Ronai Explained

Ze’ev Ronai
Workplaces:Sanford Burnham Prebys Medical Discovery Institute
Spouses:)-->
Partners:)-->

Ze’ev Ronai is an Israeli-American cancer research scientist and Chief Scientific Advisor at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla.[1] [2] [3] [4]

Education

Ze’ev Ronai was born in Haifa in 1956.[5] He attended Hugim High School in Haifa, and received his B.S. (Biology) and Ph.D. (Immunology) from the Hebrew University of Jerusalem.[6] [7] [8]

Research

Ronai's studies provide new fundamental understanding for the role and function of epigenetic components (transcription factor and ubiquitin ligases) in cancer. Early in his career he developed a sensitive PCR approach to detect mutant Ras oncogene in normal appearing tissues.[9] [10]

Later on, his studies provided the foundation for the rewired signaling in cancer,[11] by demonstrating the important role of protein subcellular localization in its oncogenic function[12] and by establishing the function of ubiquitin ligases in key cellular processes (i.e. hypoxia,[13] unfolded protein response,[14] mitochondrial dynamics,[15] anti-tumor immunity[16]) and their critical contribution to development, progression, and therapy resistance of prostate[17] and breast cancers[18] and melanoma.[19] He developed SBI-756,[20] a small molecule inhibitor, which targets the translation initiation complex, inhibiting melanoma[21] and lymphoid tumors. Ze’ev Ronai published close to 300 peer-reviewed publications, reflected in over 20,000 citations.

Following post doctoral training with I.B. Weinstein at Columbia University, Ronai began his independent career on the campus of the New York Medical College, followed by tenure at Mount Sinai School of Medicine in NY.[22] [23] He also served as SBP's Scientific Director.[24] [25]

In Israel, he has established the Technion Integrated Cancer Center, (with the Nobel Laureate Aaron Ciechanover), first in class where engineers biologists and oncologists collaborate to defeat cancer.[26]

Awards and honors

Ronai received the Lifetime Achievement Award from the Society for Melanoma Research (2016).[27] Earlier, he obtained the Golda Meir Fellowship from the Hebrew University. He also served as editor in chief of Pigment Cell & Melanoma Research.[28]

Patents

Ronai obtained a number patents for his inventions; those include a "Quantitative method for early detection of mutant alleles and diagnostic kits for carrying out the method" (1996),[29] "Inhibition of ATF2 activity to treat cancer" (2011),[30] and "Compositions and methods for inhibiting growth and metastasis of melanoma" (2011).[31]

Publications

Personal life

Ze’ev Ronai is married to Iris Ronai (1980); they have three children.

External links

Ze’ev Ronai lab page is www.ronailab.net

Notes and References

  1. Web site: Ze'ev Ronai, Ph.D. SBP. www.sbpdiscovery.org. 2019-11-22.
  2. Web site: Home SBP. www.sbpdiscovery.org. 2019-11-22.
  3. Web site: ??????????? ?????? ???????? The Hebrew University of Jerusalem . new.huji.ac.il. 2019-11-22.
  4. Web site: Nature.com.
  5. Web site: First-of-its-Kind Center Brings New Tools & Players to The Global Fight Against Cancer. ATS. 2019-11-23.
  6. Web site: Ze'ev Ronai - Professor of Immunology and Microbiology in La Jolla, California, United States of America eMedEvents. www.emedevents.com. 2019-11-22.
  7. Web site: ??????????? ?????? ???????? The Hebrew University of Jerusalem . new.huji.ac.il. 2019-11-22.
  8. Web site: Nature.com.
  9. Senft. Daniela. Leiserson. Mark D. M.. Ruppin. Eytan. Ronai. Ze'ev A.. October 2017. Precision Oncology: The Road Ahead. Trends in Molecular Medicine. 23. 10. 874–898. 10.1016/j.molmed.2017.08.003. 1471-499X. 5718207. 28887051.
  10. Kahn. S. M.. Jiang. W.. Culbertson. T. A.. Weinstein. I. B.. Williams. G. M.. Tomita. N.. Ronai. Z.. June 1991. Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene. 6. 6. 1079–1083. 0950-9232. 1676837.
  11. Lopez-Bergami. Pablo. Huang. Conway. Goydos. James S.. Yip. Dana. Bar-Eli. Menashe. Herlyn. Meenhard. Smalley. Keiran S. M.. Mahale. Alka. Eroshkin. Alexey. Aaronson. Stuart. Ronai. Ze'ev. May 2007. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 11. 5. 447–460. 10.1016/j.ccr.2007.03.009. 1535-6108. 1978100. 17482134.
  12. Lau. Eric. Kluger. Harriet. Varsano. Tal. Lee. KiYoung. Scheffler. Immo. Rimm. David L.. Ideker. Trey. Ronai. Ze'ev A.. 2012-02-03. PKCe promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell. 148. 3. 543–555. 10.1016/j.cell.2012.01.016. 1097-4172. 3615433. 22304920.
  13. Nakayama. Koh. Frew. Ian J.. Hagensen. Mette. Skals. Marianne. Habelhah. Hasem. Bhoumik. Anindita. Kadoya. Takayuki. Erdjument-Bromage. Hediye. Tempst. Paul. Frappell. Peter B.. Bowtell. David D.. 1447980. 2004-06-25. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell. 117. 7. 941–952. 10.1016/j.cell.2004.06.001. 0092-8674. 15210114. free.
  14. Scortegagna. Marzia. Kim. Hyungsoo. Li. Jian-Liang. Yao. Hang. Brill. Laurence M.. Han. Jaeseok. Lau. Eric. Bowtell. David. Haddad. Gabriel. Kaufman. Randal J.. Ronai. Ze'ev A.. May 2014. Fine tuning of the UPR by the ubiquitin ligases Siah1/2. PLOS Genetics. 10. 5. e1004348. 10.1371/journal.pgen.1004348. 1553-7404. 4014425. 24809345 . free .
  15. Kim. Hyungsoo. Scimia. Maria C.. Wilkinson. Deepti. Trelles. Ramon D.. Wood. Malcolm R.. Bowtell. David. Dillin. Andrew. Mercola. Mark. Ronai. Ze'ev A.. 2011-11-18. Fine-tuning of Drp1/Fis1 availability by AKAP121/Siah2 regulates mitochondrial adaptation to hypoxia. Molecular Cell. 44. 4. 532–544. 10.1016/j.molcel.2011.08.045. 1097-4164. 3360955. 22099302.
  16. Li. Yan. Tinoco. Roberto. Elmén. Lisa. Segota. Igor. Xian. Yibo. Fujita. Yu. Sahu. Avinash. Zarecki. Raphy. Marie. Kerrie. Feng. Yongmei. Khateb. Ali. 2 April 2019. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice. Nature Communications. 10. 1. 1492. 10.1038/s41467-019-09525-y. 2041-1723. 6445090. 30940817. 2019NatCo..10.1492L.
  17. Qi. Jianfei. Tripathi. Manisha. Mishra. Rajeev. Sahgal. Natasha. Fazli. Ladan. Fazil. Ladan. Ettinger. Susan. Placzek. William J.. Claps. Giuseppina. Chung. Leland W. K.. Bowtell. David. 2013-03-18. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell. 23. 3. 332–346. 10.1016/j.ccr.2013.02.016. 1878-3686. 3750989. 23518348.
  18. Jeon. Young Joo. Khelifa. Sihem. Ratnikov. Boris. Scott. David A.. Feng. Yongmei. Parisi. Fabio. Ruller. Chelsea. Lau. Eric. Kim. Hyungsoo. Brill. Laurence M.. Jiang. Tingting. 2015-03-09. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell. 27. 3. 354–369. 10.1016/j.ccell.2015.02.006. 1878-3686. 4356903. 25759021.
  19. Kim. Hyungsoo. Frederick. Dennie T.. Levesque. Mitchell P.. Cooper. Zachary A.. Feng. Yongmei. Krepler. Clemens. Brill. Laurence. Samuels. Yardena. Yardena Samuels. Hayward. Nicholas K.. Perlina. Ally. Piris. Adriano. 2015-06-09. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports. 11. 9. 1458–1473. 10.1016/j.celrep.2015.04.049. 2211-1247. 4681438. 26027934.
  20. Web site: Potential melanoma drug found. 2015-12-05. San Diego Union-Tribune. 2019-11-22.
  21. Feng. Yongmei. Pinkerton. Anthony B.. Hulea. Laura. Zhang. Tongwu. Davies. Michael A.. Grotegut. Stefan. Cheli. Yann. Yin. Hongwei. Lau. Eric. Kim. Hyungsoo. De. Surya K.. 2015-12-15. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Research. 75. 24. 5211–5218. 10.1158/0008-5472.CAN-15-0885. 1538-7445. 4681635. 26603897.
  22. Web site: Lab Members Ronai Lab La Jolla, California, USA. ronailab. 2019-11-23.
  23. Ronai. Ze'Ev. ATF2 in melanoma development and progression. Grantome.
  24. Web site: NCI-Designated Cancer Center SBP. www.sbpdiscovery.org. 2019-11-22.
  25. Web site: Ze'ev Ronai, Ph.D. SBP. www.sbpdiscovery.org. 2019-11-23.
  26. Web site: Technion opens new cancer research center. Press. Viva Sarah. 2016-12-04. Israel21c. 2019-11-23.
  27. Web site: Society for Melanoma Research - Awards and Honors. www.societymelanomaresearch.org. 2019-11-22.
  28. Web site: Pigment Cell & Melanoma Research. Wiley Online Library. 10.1111/(ISSN)1755-148X. 2019-11-22.
  29. Quantitative method for early detection of mutant alleles and diagnostic kits for carrying out the method. 1996-04-30. US. 5512441. American Health Foundation. Ronai. Zeey A..
  30. Inhibition of ATF2 activity to treat cancer. 2011-05-03. US. 7935525. Mount Sinai School of Medicine. Ronai. Ze'ev.
  31. Compositions and methods for inhibiting growth and metastasis of melanoma. 2011-02-15. US. 7888355. Burnham Institute for Medical Research. Ronai. Ze′ev A.. Bhoumik. Anindita. Cosford. Nicholas D. P.. Dahl. Russell.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ze'ev Ronai".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.